Global Sensation! Taiwan's Pride! AcroCyte Therapeutics Wins Runner-Up in MEDICA 2025 Start-up Competition!
News
November 19,2025
【DÜSSELDORF, Germany】
With backing from the National Science and Technology Council (NSTC), AcroCyte Therapeutics, Inc. proudly announces a monumental victory! Leveraging its globally unique R³CE® (Rapid, Reproducible, Rare Cell 3D Expansion) technology, AcroCyte soared in the MEDICA Start-up Competition 2025, securing the prestigious Runner-Up (Second Place) position worldwide.
Emerging from a highly competitive field of over 230 companies from more than 45 countries, this achievement is not only a major milestone for AcroCyte but also represents an extremely rare and distinguished honor secured by a Taiwanese startup in this premier global medical technology contest.
The competition was held on the afternoon of November 18 (German local time), where Professor Ying-Chih Chang, CEO of AcroCyte Therapeutics, personally took the stage to present the revolutionary potential of R³CE® to the international judging panel. The core R³CE® technology provides a cutting-edge Scaffold-free and Animal-free culture platform, which completely eliminates batch-to-batch variation and reduces external interference. This highly sensitive technology can rapidly expand rare cells (such as Circulating Tumor Cells, CTCs) from minimal input, ensuring the stability and reproducibility of cell spheroid size and growth efficiency. Utilizing this breakthrough, AcroCyte can effectively leverage a patient’s own cells to establish personalized
3D models, offering a foundation for more precise and rapid treatment decision-making.
AcroCyte is committed to continuously advancing the R³CE® technology with a patient-centric focus, injecting epoch-making innovation into fields like cell therapy, drug screening, and regenerative medicine. We aspire to utilize our proprietary technology in the near future to forge a new medical ecosystem where patients, physicians, and the biotech industry can mutually flourish and contribute to the profound value of life.
With backing from the National Science and Technology Council (NSTC), AcroCyte Therapeutics, Inc. proudly announces a monumental victory! Leveraging its globally unique R³CE® (Rapid, Reproducible, Rare Cell 3D Expansion) technology, AcroCyte soared in the MEDICA Start-up Competition 2025, securing the prestigious Runner-Up (Second Place) position worldwide.
Emerging from a highly competitive field of over 230 companies from more than 45 countries, this achievement is not only a major milestone for AcroCyte but also represents an extremely rare and distinguished honor secured by a Taiwanese startup in this premier global medical technology contest.
The competition was held on the afternoon of November 18 (German local time), where Professor Ying-Chih Chang, CEO of AcroCyte Therapeutics, personally took the stage to present the revolutionary potential of R³CE® to the international judging panel. The core R³CE® technology provides a cutting-edge Scaffold-free and Animal-free culture platform, which completely eliminates batch-to-batch variation and reduces external interference. This highly sensitive technology can rapidly expand rare cells (such as Circulating Tumor Cells, CTCs) from minimal input, ensuring the stability and reproducibility of cell spheroid size and growth efficiency. Utilizing this breakthrough, AcroCyte can effectively leverage a patient’s own cells to establish personalized
3D models, offering a foundation for more precise and rapid treatment decision-making.
AcroCyte is committed to continuously advancing the R³CE® technology with a patient-centric focus, injecting epoch-making innovation into fields like cell therapy, drug screening, and regenerative medicine. We aspire to utilize our proprietary technology in the near future to forge a new medical ecosystem where patients, physicians, and the biotech industry can mutually flourish and contribute to the profound value of life.